Evaluation of the effect of intracameral cefuroxime on macular and subfoveal choroidal thickness and macular sensitivity in diabetic patients after cataract surgery

Abstract

Purpose 

To evaluate the macular and subfoveal choroidal thickness variation and macular sensitivity changes in diabetic patients after intracameral cefuroxime in cataract surgery.

Setting 

Department of Ophthalmology, Shanghai Ninth People’s Hospital, Shanghai, China.

Design 

Prospective case series.

Methods 

Diabetic patients with visually significant cataract were divided into a treatment group, which received an intracameral injection of 1 mg/0.1 mL cefuroxime, and a control group, which received an equal volume of 0.9% saline solution. The macular thickness and subfoveal choroidal thickness were measured by optical coherence tomography. The macular sensitivity was assessed by microperimetry using the MP-1.

Results 

The study comprised 46 eyes of 38 patients. The macular thickness increased significantly both in the treatment group (P < .01) and the control group (P < .05) postoperatively. The mean variation was 8.27 ± μm 3.22 (SD) in the treatment eyes and 11.38 ± 7.75 μm in the control eyes. The mean preoperative subfoveal choroidal thickness was 262.86 ± 37.02 μm and 279.70 ± 54.68 μm, respectively (P = .497). No statistical difference was found in the macular thickness variation (P = .338) or subfoveal choroidal thickness variation (P = .491) between the 2 groups. For macular sensitivity, there was no significant difference in the variation between the treatment group and the control group (6.05 ± 2.37 dB versus 5.52 ± 4.17 dB) (P = .772).

Conclusion 

Intracameral cefuroxime did not significantly influence the thickening of macula or the subfoveal choroidal thickness in diabetic patients after uneventful cataract surgery. The functional improvement in macular sensitivity was also not affected.